Daiichi Sankyo Company (DSKYF) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The study, officially titled “A Randomized, Single-center, Open-label, Single-dose, 4-period, 2-sequence, Fully Replicate Crossover Study…,” evaluates whether a single fixed dose pill combining bempedoic acid, ezetimibe, and atorvastatin matches the exposure of taking the three drugs as separate tablets. It matters because an effective combo pill could make cholesterol control simpler and more reliable for high risk patients.
The treatment under review is a fixed dose tablet that combines bempedoic acid 180 mg, ezetimibe 10 mg, and atorvastatin 40 mg in one pill. The goal is to deliver the same cholesterol lowering effect as the three reference products taken together, while improving convenience and likely adherence.
The trial is an interventional Phase 1 study in healthy volunteers, using a randomized crossover design where each person receives both the combo pill and the separate tablets in different periods. There is no blinding, and the primary aim is to compare drug levels in the blood and confirm the combo tablet is bioequivalent to the reference treatments.
The study started after its initial submission on 2025-11-24, marking the launch of Daiichi Sankyo’s work on this specific combo form. The trial is listed as completed, with the most recent update filed on 2026-02-26, indicating data are locked and the company is likely preparing or reviewing full results for next steps.
For investors, a positive bioequivalence readout supports Daiichi Sankyo’s strategy in the crowded cholesterol market, where adherence friendly combo pills can carve out share despite generic pressure. The update may improve sentiment around DSKYF’s late stage cardiometabolic pipeline and positions the company against other lipid players focused on PCSK9 and oral non statin options.
The study is completed and recently updated, and further details are available on the ClinicalTrials portal.
To learn more about DSKYF’s potential, visit the Daiichi Sankyo Company drug pipeline page.